Trastuzumab is a monoclonal antibody that directly targets part of the HER2 tyrosine kinase receptor. The trastuzumab not only for make the cell surface expression of Her-2 down, but also make it be combined with with the Her-2 ECD shedding from the plasma membrane free, and inhibition of proliferation-promoting activity of Her-2 cells. In addition, The trastuzumab may effectively stop Her-2 extracellular domain shedding from the cell surface. The trastuzumab is no activity for the low level of Her-2 expression in cancer patients, but also have the effect of only 1 / 3 of patients in Her-2 overexpressing breast cancer patients.
Pertuzumab represents the first in a new class of targeted therapeutics known as HER dimerisation inhibitors. The new anti-Her-2 antibody Pertuzumab represents combined with Her-2 receptor extracellular domain zone Ⅱ to stop the formation of dimers and thus Inhibit receptor-mediated signaling pathways. It may explains part of the reason of Pertuzumab represents inhibition of Her-2 low levels of tumor growth, Pertuzumab represents are combined with Her-2 receptor extracellular Ⅳ area, Dimer formation Does not involve Ⅳ area. Therefore, trastuzumab only Her-2 overexpressing breast cancer patients effectively.
The positive rate of EGFR is different in various tumor tissues, it is closely related with the Degree of tumor differentiation and malignancy and infiltration. The Cetuximab to inhibit the action of Phosphorylation and activation of receptor kinase by blocking EGFR ligand binding and inhibits proliferation of human pulmonary adenocarcinoma cells in culture.
Other anti-EGFR monoclonal antibody therapeutic monoclonal antibody include Jesper, round the source of the monoclonal antibody IMC-11F8, identify the EGFR variant EGFRvIII monoclonal antibody mAb 806 and so on.
Researchers are currently recruiting mesothelioma patients for a Phase II study that is aimed to test the safety and effectiveness of IMC-A12 in patients who have previously been treated with standard chemotherapy methods. Researchers are currently recruiting mesothelioma patients for a Phase II study that is aimed to test the safety and effectiveness of IMC-A12 in patients who have previously been treated with standard chemotherapy methods. IMC-A12 is an antibody that is designed to block the effects of a protein called Type I Insulin-Like Growth Factor (IGF-1R), which is thought to play a role in helping cancer cells grow and divide. IMC-A12 is a new cancer treatment that has not yet been approved by the U. S. Food and Drug Administration.
the article from:Curative medicine and health site